Advertisement
Advertisement

RK-251 Was Tested Against One Cancer Cell Line. The Problem It Was Built to Solve Is Bioavailability.

RK-251 Was Tested Against One Cancer Cell Line. The Problem It Was Built to Solve Is Bioavailability.

FindingsScience read/Oncology/Small Molecule RK-251 Was Tested Against One Cancer Cell Line. The Problem It Was Built to Solve Is Bioavailability. Athithi Verma· 25 August 2026· 2 min read· Synopulse What they did A research article in the Journal of Medicinal Chemistry, published 23 July 2026 across pages 17342 to 17365. Kesarwani and colleagues at IIT … Read more

A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical

A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical

Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.

Advertisement

ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC

ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC

Findings Science read / Oncology / AI & ML ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC Athithi Verma · 18 August 2026 · 3 min read · Synopulse A Hong Kong Polytechnic University team reports that a network fusing whole slide pathology images with gene expression data reached 82.55% discrimination in classifying which … Read more